loading page

CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukaemia – a case report
  • +6
  • Ruth-Maria Urbantat,
  • Valentin Popper,
  • Elisabeth Menschel,
  • Michael Pfeilstoecker,
  • Ernst Forjan,
  • Alexander Nader,
  • Caroline Sieghart,
  • Felix Keil,
  • Elisabeth Koller
Ruth-Maria Urbantat
Hanusch Hospital
Author Profile
Valentin Popper
Hanusch Hospital
Author Profile
Elisabeth Menschel
Hanusch Hospital
Author Profile
Michael Pfeilstoecker
Hanusch Hospital
Author Profile
Ernst Forjan
Hanusch Hospital
Author Profile
Alexander Nader
Hanusch Hospital
Author Profile
Caroline Sieghart
Hanusch Hospital
Author Profile
Felix Keil
Hanusch Hospital
Author Profile
Elisabeth Koller
Hanusch Hospital
Author Profile

Abstract

CPX-351 is a promising new therapeutic option for patients with treatment related (tAML) or secondary acute myeloid leukemia (sAML). It exceeded classic 7+3 therapy in overall survival (OS) and complete remission rates (CR) while providing a similar risk profile. Until now, this sub-group of AML patients had a worse overall

Peer review status:ACCEPTED

29 Jul 2020Submitted to Clinical Case Reports
30 Jul 2020Submission Checks Completed
30 Jul 2020Assigned to Editor
01 Sep 2020Reviewer(s) Assigned
28 Oct 2020Review(s) Completed, Editorial Evaluation Pending
28 Oct 2020Editorial Decision: Revise Minor
04 Jan 20211st Revision Received
05 Jan 2021Submission Checks Completed
05 Jan 2021Assigned to Editor
05 Jan 2021Review(s) Completed, Editorial Evaluation Pending
24 Jan 2021Editorial Decision: Accept